Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToGiAC: Tocilizumab in Giant Cell Arteritis With Cerebro-vascular Involvement
NCT04888221Phase 3Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2021
- Primary completion
- Jan 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised trial in giant cell arteritis (GCA) comparing Tocilizumab with Placebo (2 arms). Primary endpoint: Percentage of patients in complete remission of GCA with absence of ischemic stroke recurrence at 24 weeks. Started Sep 2021; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT04888221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04888221.